The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of San Francisco for 2022. San Francisco and the larger bay area, including Silicon Valley, is home to some of the most revolutionary healthcare technology companies in the world. Those represented on this year’s list are innovating across a wide range of specialties, from immunotherapy to blood transfusions, ultrasound ablation, vaccines, and much more. The only way such innovation is possible is with an experienced leadership team that is able to guide an organization while keeping patient well-being front of mind — and these leaders have done just that.
Some of the distinguished leaders on this year’s list include Whitney Jones, SVP and CPO of Sangamo Therapeutics, who is responsible for all things people and culture for the genomic medicine company. Meanwhile, SVP of Customer Engagement for Genentech Kate Rowbotham leads a team of roughly 1,300 employees with responsibility for the entire Genentech portfolio of medicines, delivering approximately $25 billion in annual revenue. And Grant Pickering co-founded and is CEO and Director of Vaxcyte, which is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
This year’s awardees lead from a variety of positions, from CEO to COO, President, VP, and Chief Information Officer. What they have in common is the transformative effects they have on their organizations, all of which in the end contribute to the success of their companies and significant improvement in the lives of patients. Please join us in celebrating The Top 25 Healthcare Technology Leaders of San Francisco for 2022.
1. Sri Kosaraju
Company: Inscripta, Inc.
Title: Chief Executive Officer
Sri Kosaraju currently serves as the Chief Executive Officer of the automated genome engineering company Inscripta. He started with the company in October of 2020 after spending most of his career in the private sector working at the intersection of financial and healthcare markets. This included a 16-year period at JPMorgan Chase & Co., where he served as Head of Healthcare and Co-Head of TMT Equity Capital Markets. He also spent 5 years with Penumbra serving as CFO and later as President.
Sri Kosaraju graduated with a bachelor of science in mechanical engineering from the Massachusetts Institute of Technology. He is on the executive council and is a board member of Testing for America, and he is a member of the boards of both Nevro and 10x Genomics (and serves as the Audit Chair of the latter as well). Kosaraju is a vocal proponent of bioeconomic growth as both an economic opportunity and as a means of improving health and environmental sustainability.
2. Andrew Allen
Company: Gritstone Bio
Title: Co-Founder, President, and Chief Executive Officer
Dr. Andrew Allen has served as the President and Chief Executive Officer of Gritstone Bio since he co-founded it in 2015, creating a company that is centered on innovative immunotherapies for both cancers and infectious diseases. He also serves as a member of the Board of Directors for both Sierra Oncology and TCR2 Therapeutics Inc. Prior to co-founding Gritstone, Allen co-founded Clovis Oncology, where he served as Chief Medical Officer until 2015.
Allen received his Doctor of Philosophy from Imperial College London as well as MA, BM, and BCH degrees from the University of Oxford. After completing his education, he worked for several years at McKinsey & Company before transitioning to work in biotechnics. Allen later served in leadership roles for clinical development at Chiron Corporation and Abbott Laboratories. Currently, his work at Gritstone deals with creating neoantigens that offer unique solutions for individual patients.
3. Wilson Constantine
Company: Smiths Medical
Title: President, Americas
Dr. Wilson Constantine has served as President, Americas of Smiths Medical for over two years. During this time, he has been a member of the board of directors for both the Medical Device Manufacturers Association and Modulim. Constantine has a wealth of experience serving in leadership roles, serving as both President and Chief Executive Officer for Nihon Kohden America as well as Monarch Medical Technologies. During his time at Nihon Kohden America, he facilitated organizational improvements to make it the fastest-growing company in the market. His continued leadership roles and presence on the boards of directors for several leading organizations speaks to his knowledge and experience in the industry.
Constantine holds a doctorate from Samuel Merritt University. He graduated from Loma Linda University with a degree in biology and from the Executive Management Program of the Mendoza College of Business at the University of Notre Dame. After completing his education, he served as a vice president for several Fortune 500 companies, including Henry Schein and Stryker. His experience in medtech culture and strategy make him an industry leader and a sought-after speaker at industry events.
4. Stefani Wolff
Company: Nurix, Inc.
Title: Chief Operating Officer and Executive Vice President of Product Development
Stefani Wolff has served as Chief Operating Officer and Executive Vice President of Nurix Therapeutics since June of 2021. She has worked in biotech for most of her career, including as Senior Director for Genentech and Chief Development Officer for Principia Biopharma. She is also currently a member of the board of directors for Rain Therapeutics, Inc. Wolff has been instrumental in the launches of products including Rituxan, Avastin, and Imbruvica. Her work has given her a wealth of knowledge on both the pharma and biotech sectors.
Wolff graduated from the University of North Carolina at Chapel Hill with a Bachelor of Pharmacy degree and a Bachelor of Science in chemistry. She held several leadership positions in companies before her time at Nurix, such as Vice President of Development at Onyx Pharmaceuticals, Inc. Her experience was essential in the founding of the Oncology business at Genentech. In total, Wolff has over 3 decades of experience in immunology and oncology that she utilizes to provide valuable leadership and expertise for Nurix.
5. William Greenman
Company: Cerus
Title: President and Chief Executive Officer
William “Obi” Greenman has served as President and Chief Executive Officer of Cerus for over a decade. He has been with the company for more than 27 years, serving in several roles including Vice President of Business Development and Marketing, President of Cerus Europe, and Chief Business Officer. He currently serves on the board of directors for Chinook Therapeutics and has served on the board of Aduro Biotech in the past. During his time at Cerus, he has been instrumental in the securing of four patents in the field of transfusion medicine, making him a pioneer in medical technology.
Greenman graduated with a bachelor’s degree in biological sciences and economics from Stanford University. Prior to Cerus, he worked in Baxter International Inc.’s Biotech Division as Manager of Corporate Development. Over his career at Cerus, Greenman has played a central role in the creation of the company’s European operations, partnering with the Swiss Red Cross to support blood transfusions in sub-Saharan Africa and overseeing FDA approval for Cerus products.
6. Whitney Jones
Company: Sangamo Therapeutics, Inc.
Title: Senior Vice President and Chief People Officer
Whitney Jones is the Senior Vice President and Chief People Officer of Sangamo Therapeutics, Inc. She first joined the company in 2020. Sangamo Therapeutics is a genomic medicine company that applies cell and gene therapy to combat hemophilia and other genetic diseases. Its goal is to develop a wholly owned genomic medicine portfolio, which it funds via its collaborations with blue-chip biopharmaceutical partners that have already brought in $815 million in upfronts and milestones, with billions in potential milestone payments. Sangamo Therapeutics believes that manufacturing is a strategic advantage and gives it greater control over timelines, quality, and supply. Its ability to fund its projects enables it to execute and deliver on its mission. Sangamo Therapeutics aims to transform patients’ lives by replacing today’s symptom-focused treatments with tomorrow’s genomic cures.
Previously, Jones was Chief People Officer at LendingClub, and before that, Global Head of HR at Novartis Diagnostics. Earlier in her career, she worked with The Coca-Cola Company – Czech & Slovak Republics as a regional HR manager. She earned an undergraduate degree in history from the University of Vermont.
7. Kate Rowbotham
Company: Genentech
Title: Senior Vice President of Customer Engagement
Kate Rowbotham is the Senior Vice President of Customer Engagement at Genentech. Genentech pursues groundbreaking science to discover and develop innovative medicines for people facing serious and life-threatening diseases. It has the largest biotech research center in the world and it markets approximately 40 medicines, including 13 medicines for cancer. Its transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. Genentech is testing new medicines with the hope of helping people with serious diseases live longer and better lives, and it is committed to developing personalized medicines and getting the right medicine to the right patient. Historically, the company is regarded as the world's first biotechnology company.
Before joining Genentech, Rowbotham was a business planning associate at Biogen. Earlier in her career, she worked with Navigant Consulting as a consultant. Rowbotham graduated from The Tuck School of Business at Dartmouth with an MBA, and from Tufts University with an undergraduate degree in chemical engineering.
8. Hamta Podesta
Company: Dermavant Sciences
Title: Senior Director and Field Medical Team Leader
Hamta Podesta is a Senior Director and the Field Medical Team Leader for Dermavant Sciences, a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. It is dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients’ lives. The patient is at the heart of everything Dermavant does.
Previously, Podesta was Head of the Field Medical Scientist Team at Allakos, Inc., and before that, the Executive Director of Medical Science Liaisons at ZS Pharma, Inc. (a member of the AstraZeneca Group). She earned her PhD in biochemistry and her Master of Science in pharmacology from the University of California at Santa Barbara.
9. Krish Krishnan
Company: Krystal Biotech, Inc.
Title: Chairman and Chief Executive Officer
Krish Krishnan is the Chairman and Chief Executive Officer of Krystal Biotech, a clinical-stage gene therapy company using its proprietary, engineered virus vector platform to develop effective and innovative treatments for skin diseases. The company’s mission is to make a meaningful difference in the lives of underserved patient populations suffering from debilitating skin diseases. It works to accomplish this goal through scientific innovation and operational excellence, believing, like Aristotle said, that "nature operates in the shortest way possible.” While the company is initially developing topical and intradermal "off-the-shelf" novel therapies for rare and orphan dermatological indications, it is expanding the use of its pioneering gene technology to target and treat other rare diseases.
Previously, Krishnan served as Senior Managing Director at Third Security LLC. From there, he went on to New River Pharmaceuticals, before eventually rising to COO at Intrexon Corporation, his most recent position prior to joining Krystal Biotech. Krishnan graduated from The Wharton School of the University of Pennsylvania with an MBA in finance and from the Indian Institute of Technology with an undergraduate degree in engineering.
10. Andrew Weiss
Company: ReCor Medical
Title: President and Chief Executive Officer
Andrew Weiss is the President and Chief Executive Officer of ReCor Medical. He first joined the company in 2013. ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The company is a pioneer of ultrasound renal denervation (uRDN) technology that can lower high blood pressure by treating overactive renal nerves (through a one-time minimally invasive procedure) with ultrasound energy. ReCor Medical also created the RADIANCE Global Program, an international, multicenter, first-of-its-kind initiative designed to explore the benefits of renal denervation in hypertension.
Previously, Weiss was President and CEO of CoAxia, and before that, Vice President of Corporate Science and Technology at Medtronic. Earlier in his career, he worked with Booz Allen Hamilton as an associate. Weiss earned an MBA in marketing and strategy from Columbia Business School, and an undergraduate degree in mechanical and electrical engineering from the Massachusetts Institute of Technology.
11. Grant Pickering
Company: Vaxcyte
Title: Co-Founder, Chief Executive Office, and Director
Grant Pickering is the Co-Founder, Chief Executive Officer, and Director of Vaxcyte, a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.
Before joining Vaxcyte, Pickering was an independent director at SmartVet Holdings, Inc., and before that, a strategic advisor at Atreca, Inc. Earlier in his career, he worked with Johnson & Johnson: Ortho Pharmaceutical Corporation as a professional sales representative. Pickering graduated from the Georgetown University McDonough School of Business with an MBA, and from Penn State University with an undergraduate degree in marketing.
12. Jeffrey Bluestone
Company: Sonoma Biotherapeutics
Title: President and Chief Executive Officer
Jeffrey Bluestone is the President and Chief Executive Officer of Sonoma Biotherapeutics. Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Bio creates best-in-class Treg therapies that are long-lasting, highly efficacious, and have the potential to slow or prevent disease progression and prolong healthy life.
Previously, Bluestone was a professor and director of the Ben May Institute for Cancer Research at The University of Chicago. From there, he went on to Immune Tolerance Network, before eventually rising to Executive Vice Chancellor and Provost at the University of California, San Francisco, his most recent position prior to joining Sonoma Biotherapeutics. Bluestone graduated from Cornell University with a PhD in immunology, and from Rutgers University with an undergraduate degree in biology.
13. Darren Platt
Company: Demetrix
Title: President and Chief Information Officer
Darren Platt is the President and Chief Information Officer of Demetrix. He first joined the company in 2017 as CIO. Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients. The company identifies rare bioactive compounds and, through rigorous research, develops those with the greatest potential for human health and wellbeing. Demetrix methods replicate nature’s chemistry, producing bioactives efficiently and affordably while maintaining a light environmental footprint. The company's system uses genetics and computing enabled deciphering technology to produce co-evolved and bio-inspired cannabinoids medicines and nutraceuticals in genetics, synthetic biology, and data science, enabling physicians to understand and harvest biology to create bio-inspired medicines and nutraceuticals for gene synthesis.
Previously, Platt was Vice President of Data Science at Amyris, and before that, Senior Director of Research at 23andMe. Earlier in his career, he worked with Exelixis as Director of Bioinformatics. Platt earned a PhD in computer science, genetics, and biochemistry from Monash University.
14. Matt Brokaw
Company: Aerin Medical
Title: President and Chief Executive Officer
Matt Brokaw is the President and Chief Executive Officer of Aerin Medical. Aerin Medical offers ENT physicians a portfolio of non-invasive, office-friendly products to fill the unmet needs of people suffering from chronic nasal airway conditions. Its mission is to provide ENTs with advanced treatment options for chronic nasal conditions that positively affect the quality of life of millions of patients. Aerin believes that patients deserve the freedom to breathe better and live better, so that they can get back to living the life they love.
Before joining Aerin Medical, Brokaw was Vice President of Sales & Marketing at Smith & Nephew, and before that, VP of Sales & Marketing at Tusker Medical, Inc. Earlier in his career, he worked with Advisory Board Company as a senior consultant. Brokaw graduated from the Stanford University Graduate School of Business with an MBA, and from Williams College with an undergraduate degree.
15. Greg Bullington
Company: Magnolia Medical Technologies
Title: Co-Founder and Chief Executive Officer
Greg Bullington is a Co-Founder and the Chief Executive Officer of Magnolia Medical Technologies. Magnolia develops, manufactures, and markets innovative blood and bodily fluid collection devices to facilitate significant improvements in the accuracy, consistency, and predictability of critical laboratory tests. Today, it offers healthcare institutions a solution to some of their biggest hidden problems, such as contamination leading to misdiagnosis of bloodstream infections, including sepsis, which can lead to unnecessary and prolonged antibiotic therapy and false-positive CLABSIs. Tomorrow, it aspires to create a world free of in-vitro diagnostic errors in which rapid, accurate test results improve the lives of patients and providers alike.
Bullington first got his start in 2003 as a consultant at Lake Partners Strategy Consultants, before eventually rising to principal and founder at Forum Ventures, his most recent position prior to joining Magnolia. Bullington graduated from the University of Washington – Michael G. Foster School of Business with an undergraduate degree in business administration, finance, and international business.
16. Sumita Ray
Company: Instil Bio
Title: Chief Legal, Compliance & Administrative Officer and Corporate Secretary
Sumita Ray is the Chief Legal, Compliance & Administrative Officer and Corporate Secretary for Instil Bio. Instil is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient’s own T cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. Instil is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered TIL.
Ray is a global biotech executive and industry veteran with over 20 years of experience spanning the life sciences sector in private law firm practice, as well as large pharma, mid-size and small biotechs, and start-ups. She has a broad set of experiences in leadership roles with a wide-spectrum of early to late-stage companies, including strategy development/execution, commercialization, legal and regulatory/compliance, and various business operations. She has a track record of proven success in a team-based approach for building organizations for successful product launches and bringing blockbuster therapies to market, while driving corporate strategy with operational expertise and deep knowledge across key business units.
Prior to Instil, Ray served as Chief Legal, Compliance & Administrative Officer for Calithera Biosciences and as general counsel for a number of companies, including AstraZeneca and Genentech. She holds a JD from the Temple University – James E. Beasley School of Law and a Bachelor of Science in microbiology and chemistry from the University of Arizona.
17. Laurent Fischer
Company: Adverum Biotechnologies, Inc.
Title: President and Chief Executive Officer
Laurent Fischer is the President and Chief Executive Officer of Adverum Biotechnologies, Inc. He first joined the company in 2020. Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.
Previously, Fischer was Senior Vice President and Liver Therapeutic Area Head at Allergan, and before that, Chief Executive Officer of Tobira Therapeutics. Earlier in his career, he worked with Hoffmann-La Roche as a medical director. Fischer earned an MD from the University of Geneva.
18. Federico Vegh
Company: Stämm Biotech
Title: Founder and Chief Operating Officer
Federico Vegh is the Founder and Chief Operating Officer of Stämm Biotech, a biotechnology company dedicated to making biomanufacturing easy, scalable, and repeatable. It has developed the first methodology for continuous industrial production of biologics and cell therapies leveraging microfluidics and 3D printing. Stämm Biotech’s focus is on decentralizing bioprocesses and democratizing access to biotechnology products, thus freeing its partners to focus on the disruptive discoveries that make an impact on people’s life.
Before joining Stämm Biotech, Vegh was a revenue specialist at Best Day Travel, and before that, a corporate sales account executive at Galerías Hotel Boutique Concept. Earlier in his career, he worked with Sayco-Aike as a sales associate.
19. James Bullard
Company: Pendulum Therapeutics
Title: Co-Founder and Chief Technology Officer
James Bullard is the Co-Founder and Chief Technology Officer of Pendulum Therapeutics. Pendulum Therapeutics integrates laboratory science and computational analysis to gain a comprehensive view of each individual's microbiome through targeted probiotics and prebiotics, thus enabling clinicians to identify specific microbiome markers and interventions to treat diseases. Its mission is to empower people with products and nutritional information that help them live healthy, well-balanced lives. To that end, Pendulum aims to create products that have the power and efficacy of a pharmaceutical with the safety and accessibility of a probiotic.
Previously, Bullard was a senior staff scientist at Pacific Biosciences. He graduated from the University of California, Berkeley with a PhD in biostatistics, and from Northwestern University with an undergraduate degree in computing and information systems.
20. Amy Sehnert
Company: Bristol Myers Squibb
Title: Vice President and Head of Cardiomyopathy and Heart Failure Clinical Development
Amy Sehnert is the Vice President, and Head of Cardiomyopathy and Heart Failure Clinical Development at Bristol Myers Squibb, a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. The company works every day to transform patients’ lives through science. It has built a sustainable pipeline of potential therapies and is leveraging translational medicine and data analytics to understand how it can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Its mission is to give new hope to help patients prevail in their battles with disease.
Before joining Bristol Myers Squibb, Sehnert was Vice President of Clinical Research at MyoKardia, and before that, a medical director at GRAIL, Inc. Earlier in her career, she worked with CardioDx Inc. as a director of clinical research and development. Sehnert graduated from the University of California, San Francisco with an MD, and from the University of Minnesota Medical School with an MD.
21. Signe Haughton
Company: Medtronic
Title: Senior Director of Medical & Government Affairs and Chief of Staff
Signe Haughton is the Senior Director of Medical & Government Affairs and Chief of Staff at Medtronic. She first joined the company in 2020 as Director of Government Affairs. Medtronic is a global producer of medical devices and therapies such as insulin pumps, pacemakers, and diabetes therapies. Perhaps best known for its revolutionary cardiac devices, such as battery-powered and miniature pacemakers, it has routinely introduced cutting-edge products into the industry. It also provides biologic solutions for the orthopedic and dental markets. Medtronic fuses technology, a deep understanding of the body, and leading medical science to create never-before-seen solutions. Whether it’s less invasive surgical approaches to minimize a patient's downtime or creating the smallest pacemaker, Medtronic’s potential to transform lives knows no limits.
Previously, Haughton was a director of global strategic alliances at Stryker Neurovascular, and before that, a director of marketing at Boston Scientific. Earlier in her career, she worked with the Medical College of Wisconsin as a director of clinical research. Haughton earned an undergraduate degree from the University of Wisconsin – Whitewater.
22. Mark Dresser
Company: Gilead Sciences
Title: Senior Vice President of Biomarker Sciences and Clinical Pharmacology
Mark Dresser is the Senior Vice President of Biomarker Sciences and Clinical Pharmacology for Gilead Sciences, a research-based biopharmaceutical company. With each new discovery and investigational drug candidate, Gilead seeks to improve the care of patients living with life-threatening diseases around the world. It is engaged in the discovery, development, and commercialization of medicines for the treatment of cardiovascular, hematological, and respiratory diseases, inflammation, liver diseases, cancer, and human immunodeficiency virus (HIV) infection. Since its founding in 1987, Gilead has become a leading biopharmaceutical company with a rapidly expanding product portfolio, a growing pipeline of investigational drugs, and 8,900 employees in offices across six continents. Millions of people around the world are living healthier lives because of innovative therapies developed by Gilead.
Before joining Gilead Sciences, Dresser was a Senior Vice President and Head of Development Sciences at Denali Therapeutics, and before that, a director and head of oncology at Genentech. Earlier in his career, he worked with Johnson & Johnson as an associate director of clinical pharmacology. Dresser graduated from the University of California, San Francisco with a PhD in pharmaceutical chemistry, and from Rensselaer Polytechnic Institute with a Master of Science in chemistry and an undergraduate degree in chemistry.
23. Pablo Gersberg
Company: Neumora
Title: Senior Vice President of Business Technology & Digital Health
Pablo Gersberg is the Senior Vice President of Business Technology & Digital Health at Neumora, a clinical-stage biopharmaceutical company leveraging advanced data science and artificial intelligence to develop targeted treatments for neurobehavioral disorders. Its proprietary toolbox of state-of-the-art neural network technologies is built to integrate multiple types of data across genomics, imaging, electroencephalogram (EEG), and digital and clinical domains to create Data Biopsy Signatures™ that map the underlying disease mechanisms to Precision Phenotypes™ that identify distinct patient subtypes. Through this approach, Neumora has the ability to develop and match the right therapeutic to the right patient populations for more targeted treatments. It is focused on conquering one of the greatest medical challenges of our generation: the global brain disease crisis.
Prior to Neumora, Gersberg was a principal at PwC. From there, he went on to Cambridge Technology Partners, before eventually rising to director of digital health at Amgen, his most recent position prior to joining Neumora. Gersberg graduated from Florida International University with an MBA, and from the University of Florida with an undergraduate degree in engineering.
24. Tony Taricco
Company: PRC Clinical
Title: Co-Founder, President, and Chief Operating Officer
Tony Taricco co-founded PRC Clinical in 2003 and is now the company’s President and Chief Operating Officer. PRC Clinical provides specialty contract research organization (CRO) services to biotech and pharmaceutical companies. Its innovative approach to executing studies combines high-touch human elements and cutting-edge technology with extensive experience and deep therapeutic knowledge. PRC Clinical believes that highly specialized early-phase trials deserve high-touch approaches to ensure high-quality results. PRC goes the extra mile to account for every aspect of a client's project, so clients can rest assured that their trial is being handled with the utmost care.
As President and COO of PRC, Taricco is responsible for the general business operations and finance activities of the company, as well as human resources and clinical payment services. His business degree and extensive practical experience in business growth give him the unique perspective of understanding the values and challenges of a small business and molding those into a strong foundation for long-term expansion. Previously, Taricco was an AVP at Republic Indemnity. He earned an undergraduate degree in finance and banking from San Francisco State University.
25. Henry Tse
Company: Cytovale
Title: Co-Founder and Chief Technology Officer
Henry Tse is the Chief Technology Officer of Cytovale, a medical diagnostics company he co-founded in 2013 that is focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. The company’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Its investigational IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful.
Tse leads research and development efforts to commercialize the microfluidic deformability cytometry technology. His science and engineering expertise spans microfluidics, cancer biology, image processing, and application proof-of-concept clinical studies. He is the co-inventor of the deformability cytometry platform, which has resulted in peer-reviewed publications of the technology as well as an accompanying suite of issued patents. Before joining Cytovale, Tse was an applied microfluidics researcher at the UCLA Henry Samueli School of Engineering and Applied Science. He graduated from the University of California, Los Angeles with a PhD in biomedical and medical engineering, and from the University of California, San Diego with an undergraduate degree in bioengineering and biomedical engineering.
